• Diadem Presents Data at 2023 AAIC® Showing its AlzoSure® Blood Test Can Identify Patients at High Risk of Cognitive Decline due to Alzheimer’s Disease
    Milan, Italy and Amsterdam, Netherlands, July 19, 2023
    Diadem srl, a company developing the first blood-based test for the early prediction of clinical progression to Alzheimer’s disease (AD), today announced that study data being presented at the Alzheimer’s Association International Conference® 2023 (AAIC®) further strengthens the evidence supporting the prognostic value of Diadem’s AlzoSure®Predict blood-based biomarker test, which can accurately identify whether or not individuals over the age of 50 will experience a significant cognitive decline due to AD years before the full onset of symptoms. The study data are included in a scientific poster that is being presented today at AAIC®2023.